Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism
12/9 04:21
(RTTNews) - Ascendis Pharma A/S (ASND) said that the U.S. Food & Drug Administration has granted Orphan Drug exclusivity to YORVIPATH (palopegteriparatide, developed as TransCon PTH), providing seven years of market exclusivity for YORVIPATH in the United States for the treatment...